Galux closed a ₩42 billion (US$29 million) Series B to scale AI‑driven antibody design capabilities and move programs into discovery and preclinical optimization. The funding will be used to expand computational platforms and accelerate protein engineering workflows. QuantX Biosciences raised an $85 million Series B led by Lilly and Sanofi Ventures to advance its immunology pipeline and AI‑enabled discovery. Both financings underscore continuing investor interest in companies applying machine learning to antibody engineering and target selection.